BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
We’re not sharing this information to scare, but instead to inform on the challenges the healthcare industry is facing. With that in mind, below we report on 21 innovative efforts from leading and emerging players in the biotech industry to combat the COVID-19 pandemic.
BioIDEA and EVQLV are hosting a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
The World Health Organization (WHO), yesterday, released a public statement for collaboration on COVID-19 treatment development of which Andrew Satz (CEO, EVQLV) gladly joined his name.
Our very own Brett Averso (CTO, EVQLV) was welcomed on the AI Podcast in 26.1 Minutes with hosts Brian Ray and Don Sheu. They discussed our work on COVID-19 with ImmunoPrecise, the benefits of a computational approach to antibody research and drug discovery, our progress as a company and a host of other topics.
Edward Turner of TMR Blog recently covered our work on COVID-19. He did a nice job summarizing the potential efficacy of our algorithm in an understandable and digestible manner, while including EVQLV’s optimism on the project.
Brett Averso (CTO, EVQLV) shows and explains the undeniable structural similarities between SARS-CoV-2 and SARS. We hope this video serves to dispel some of the myths you may have encountered during your search for answers surrounding coronavirus.
Our work with ImmunoPrecise on COVID-19 was covered by insideBIGDATA. They did a fantastic job covering the piece originally published by Columbia Data Science Institute, highlighting a few fantastic quotes
EVQLV, has submitted their first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2. These DNA sequences were generated using computational antibody design, a method which combines mathematics, statistics, and computer science to identify high-affinity antibodies.
The SARS antibodies are not cross-reactive with SARS-Cov-2. However, we can potentially use artificial intelligence to design variants of the existing SARS antibodies which are cross-reactive with SARS-CoV-2.